455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
EADV Analyst and Investor Event October 1, 2026
Other Events
Nektar Therapeutics Enters Quiet Period Ahead of Phase 2b Study Data
Announces Second Quarter 2026 Financial Results
Director Election Results at Nektar Therapeutics Annual Meeting
Nektar Therapeutics Enters $150 Million Equity Distribution Agreement
Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Q2
FY 2025
Q3
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership